Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lanyan Fang

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Clinical Pharmacology and Therapeutics|November 25, 2020
Public Workshop Summary Report on Fiscal Year 2021 Generic Drug Regulatory Science Initiatives: Data Analysis and Model-Based BioequivalenceJieon Lee, Yuqing Gong, Sid Bhoopathy, et al.
Journal of Medicinal Chemistry|April 2, 2005
Syntheses and biological activities of rebeccamycin analogues with uncommon sugarsGuisheng Zhang, Jie Shen, Hao Cheng, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 12, 2022
Quantitative methods and modeling to assess COVID-19-interrupted in vivo pharmacokinetic bioequivalence studies with two reference batchesYuqing Gong, Kairui Feng, Peijue Zhang, et al.
Eclinicalmedicine|September 29, 2021
Association of partial systemic exposure and abuse potential for opioid analgesics with abuse deterrence labeling claims supporting product-specific guidanceLiang Zhao, Zhichuan Li, Lanyan Fang, et al.
The AAPS Journal|October 30, 2020
New Model-Based Bioequivalence Statistical Approaches for Pharmacokinetic Studies with Sparse SamplingFlorence Loingeville, Julie Bertrand, Thu Thuy Nguyen, et al.
Pharmaceutical Research|July 15, 2006
Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat modelXianhua Cao, Seth T Gibbs, Lanyan Fang, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 16, 2022
Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studiesMélanie Guhl, François Mercier, Carsten Hofmann, et al.
Clinical Pharmacology and Therapeutics|November 12, 2024
Narrow Therapeutic Index Drugs: FDA Experience, Views, and OperationsMark Donnelly, Lanyan Fang, Rajanikanth Madabushi, et al.
Clinical Pharmacology and Therapeutics|January 18, 2025
A 2024 Update on US FDA Implementation of Partial Area Under the Curve Into Bioavailability and Bioequivalence AssessmentsRobert Hopefl, Yuqing Gong, Elizabeth Bielski, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 11, 2023
Regulatory utility of mechanistic modeling to support alternative bioequivalence approaches: A workshop overviewAndrew Babiskin, Fang Wu, Youssef Mousa, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Clinical Pharmacology and Therapeutics|November 25, 2020
Public Workshop Summary Report on Fiscal Year 2021 Generic Drug Regulatory Science Initiatives: Data Analysis and Model-Based BioequivalenceJieon Lee, Yuqing Gong, Sid Bhoopathy, et al.
Journal of Medicinal Chemistry|April 2, 2005
Syntheses and biological activities of rebeccamycin analogues with uncommon sugarsGuisheng Zhang, Jie Shen, Hao Cheng, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 12, 2022
Quantitative methods and modeling to assess COVID-19-interrupted in vivo pharmacokinetic bioequivalence studies with two reference batchesYuqing Gong, Kairui Feng, Peijue Zhang, et al.
Eclinicalmedicine|September 29, 2021
Association of partial systemic exposure and abuse potential for opioid analgesics with abuse deterrence labeling claims supporting product-specific guidanceLiang Zhao, Zhichuan Li, Lanyan Fang, et al.
The AAPS Journal|October 30, 2020
New Model-Based Bioequivalence Statistical Approaches for Pharmacokinetic Studies with Sparse SamplingFlorence Loingeville, Julie Bertrand, Thu Thuy Nguyen, et al.
Pharmaceutical Research|July 15, 2006
Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat modelXianhua Cao, Seth T Gibbs, Lanyan Fang, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 16, 2022
Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studiesMélanie Guhl, François Mercier, Carsten Hofmann, et al.
Clinical Pharmacology and Therapeutics|November 12, 2024
Narrow Therapeutic Index Drugs: FDA Experience, Views, and OperationsMark Donnelly, Lanyan Fang, Rajanikanth Madabushi, et al.
Clinical Pharmacology and Therapeutics|January 18, 2025
A 2024 Update on US FDA Implementation of Partial Area Under the Curve Into Bioavailability and Bioequivalence AssessmentsRobert Hopefl, Yuqing Gong, Elizabeth Bielski, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 11, 2023
Regulatory utility of mechanistic modeling to support alternative bioequivalence approaches: A workshop overviewAndrew Babiskin, Fang Wu, Youssef Mousa, et al.
Pageof 7